From: Rational mutagenesis to support structure-based drug design: MAPKAP kinase 2 as a case study
Rationale | Constructs |
---|---|
N- and C-terminal variations | MK2(36–400, K93R) MK2(41–364) MK2(47–357) MK2(47–366) |
Entropy-reducing surface mutations | MK2(41–364, K64A) MK2(41–364, K343A, E344A) MK2(47–366, K84A) MK2(47–366, E88A, K89A) |
Activation loop deletions | MK2(41–364, Δ(L220-G238)) MK2(47–366, Δ(L220-G238)) |
Pseudoactivation mutations | MK2(41–364, T222E) MK2(41–364, T334E) MK2(41–364, T222E, T334E) MK2(47–366, T222E) MK2(47–366, T334E) MK2(47–366, T222E, T334E) |